-
公开(公告)号：US12091464B2
公开(公告)日：2024-09-17
申请号：US17740849
申请日：2022-05-10
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITé DE NANTES , OSE IMMUNOTHERAPEUTICS
IPC分类号： A61P35/00 , C07K14/47 , C07K16/28 , C12N15/115
CPC分类号： C07K16/2851 , A61P35/00 , C07K14/4726 , C12N15/115 , C07K2317/732 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
-
公开(公告)号：US11884723B2
公开(公告)日：2024-01-30
申请号：US16979627
申请日：2019-03-13
CPC分类号： C07K16/2803 , A61K45/06 , C07K2317/565 , C07K2317/76
摘要： The invention is in the field of immunotherapy. The present invention provides antibodies useful in therapeutic and diagnostic applications targeting human SIRPa, said antibodies enhancing the cross-presentation of antigens to T cells. The invention also provides antibodies against specific isoforms of SIRP a and able to disrupt the interaction between those isoforms of SIRP a and human CD47 for use in treating or preventing a disease, or diagnostic applications, and methods for producing and/or selecting anti-human SIRPa antibodies that bind with different affinities to various isoforms of human SIRP members.
-
公开(公告)号：US11365257B2
公开(公告)日：2022-06-21
申请号：US16343757
申请日：2017-10-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ DE NANTES , OSE IMMUNOTHERAPEUTICS
IPC分类号： A61P35/00 , C07K14/47 , C12N15/115 , C07K16/28
摘要： The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
-
4.发明申请公开(公告)号：US20180312600A1
公开(公告)日：2018-11-01
申请号：US15769689
申请日：2016-10-21
IPC分类号： C07K16/28 , C12N5/0786 , A61P35/00
CPC分类号： C07K16/2803 , A61K2039/505 , A61K2039/507 , C07K16/2827 , C07K16/2878 , C12N15/1138 , C12N2310/14 , C12N2320/31
摘要： The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.
-
公开(公告)号：US20240084019A1
公开(公告)日：2024-03-14
申请号：US17767606
申请日：2020-10-09
CPC分类号： C07K16/2866 , A61P35/00 , A61P37/06
摘要： The present invention provides humanized anti-CMKLR1 compounds having an agonist capability on the interaction between Resolvin E1 and CMKLR1, and their uses for treating or preventing a disease, in particular wherein the resolution of inflammation is delayed or disrupted.
-
公开(公告)号：US20220298259A1
公开(公告)日：2022-09-22
申请号：US17747798
申请日：2022-05-18
IPC分类号： C07K16/28 , C12N15/113 , A61P35/00 , C12N5/0786
摘要： The present disclosure concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this disclosure allows to treat cancer through an indirect pathway involving the immune system.
-
7.发明公开公开(公告)号：US20240279352A1
公开(公告)日：2024-08-22
申请号：US18644720
申请日：2024-04-24
IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C12N5/0786 , C12N15/113
CPC分类号： C07K16/2896 , A61P35/00 , C07K16/2803 , C07K16/2827 , C07K16/2878 , C12N5/0645 , C12N15/1138 , A61K2039/505 , A61K2039/507 , C07K2317/76 , C12N2310/14 , C12N2320/31
摘要： The present invention concerns the use of an anti-SIRPa compound able to inhibit the polarization of anti-inflammatory M2-type macrophages and/or favors pro-inflammatory M1-type macrophages. In a preferred embodiment, such compound is used to treat cancer. Interestingly, this invention allows to treat cancer through an indirect pathway involving the immune system.
-
公开(公告)号：US11279766B2
公开(公告)日：2022-03-22
申请号：US16093062
申请日：2017-04-14
发明人： Nicolas Poirier , Caroline Mary , Bernard Vanhove , Vanessa Gauttier , Virginie Thepenier , Sabrina Pengam
摘要： The present invention provides new anti-SIRPa antibodies able to specifically antagonize the interaction between SIRPa and CD47, without affecting the interaction between SIRPg and CD47, and their uses.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.014 秒)
